- World Pharma News Home » Product » Novartis decides not to pursue further development of Aurograb(TM)
(a free service delivered by FeedBurner)
Novartis has decided not to pursue further development of the pharmaceuticals pipeline project Aurograb(TM), an add-on therapy to antibiotics that was being assessed for use in treating deep-seated staphylococcal infections, following a review of recent Phase II clinical data showing a lack of efficacy.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments